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A comparison between the use of recombinant hirudin and heparin
during heinodialysis. The purpose of this study was to determine the
anticoagulant and antithrombotic potential of hirudin during hemodialysis
by comparing the efficacy of dialysis with heparin to that of dialysis with
recombinant hirudin (r-hirudin). Eleven patients with chronic renal failure
and on maintenance hemodialysis were included in this open cross-over
study. Conventional doses of heparin were administered during the first
dialysis of the study. Two days later r-hirudin, at a dose of 0.15 mg/kg, was
given as a bolus at the start of the second dialysis. The mean decreases in
plasma levels of urea, uric acid and creatinine were approximately 50%
after dialysis with both anticoagulants. Dialysis was therefore equally
effective. However, effective dialysis with r-hirudin was achieved with a
shorter activated partial thromboplastin time (APTF; range 65 to 103
seconds) compared to that with heparin 120 seconds), thereby decreas-
ing the risk of bleeding. Markedly less ' In-labeled platelets accumulated
at the inlet of the artificial kidney when r-hirudin was used, suggesting a
smaller loss of hollow fiber volume. The results indicate that hirudin may
be a suitable alternative anticoagulant for use during hemodialysis and it
thus warrants further investigation.
Extracorporeal thrombogenesis is a major problem associated
with hemodialysis. The composition of the artificial membrane in
the extracorporeal system and the large surface area to which the
blood is exposed, contribute significantly to activation of the
coagulation cascade, white blood cells and blood platelets [1]. The
use of an anticoagulant is therefore a prerequisite to prevent
thrombotic occlusion of the artificial kidney to ensure effective
dialysis. Standard unfractionated heparin is currently the antico-
agulant of choice. Its anticoagulant effect is achieved through
interaction with the natural thrombin inhibitor, antithrombin III
(AT III). Heparin potentiates the inactivation of thrombin by
forming a complex with its cofactor AT III, which serves as a
template to which thrombin binds [2]. Heparin does, however, not
completely prevent thrombogenesis [3], and there are several
complications associated with its long-term use. These include
thrombocytopenia, increased bleeding tendency, osteoporosis,
increased lipolytic activity, and changes of lipid patterns [4—81.
Activation of lipolysis by heparin during hemodialysis also leads to
immunosuppressive effects [71. Therefore a safer and more effec-
tive anticoagulant would be beneficial.
Hirudin, the most potent natural inhibitor of thrombin, seems
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to be a promising alternative anticoagulant for heparin. Hirudin is
a direct thrombin inhibitor and does not require endogenous
cofactors. It reacts with thrombin in a 1:1 molar ratio to form a
noncovalent complex. The carboxy terminal region of hirudin,
which is rich in acidic residues, binds ionically to the anion binding
exocite of thrombin. The amino-terminal region binds via hydro-
phobic interaction to the apolar binding site and the Pro 46-Lys
47-Pro 48 region occupies the basic specificity pocket of the active
site [9]. Through this mechanism hirudin inhibits all the actions of
thrombin and so effectively inhibits coagulation and prevents
heparin-resistant arterial-type thrombosis when given in large
enough dosages [10]. Hirudin has no adverse effects when infused
into humans, because it is pharmacologically virtually inert [11].
Hirudin is also a weak immunogen [12—14]. Hirudin was first used
during hemodialysis in 1926 [15]. However, impurities in the crude
preparation and the uncertainty about its anticoagulant activity
and side effects limited its clinical use. Purified hirudin is now
made in sufficient amounts by recombinant technology, and its use
during hemodialysis has already been studied in dogs [16] and
man [17]. We evaluated the use of recombinant hirudin as an
anticoagulant during hemodialysis in humans. We assessed the
efficacy of dialysis by comparing r-hirudin with heparin. To
achieve this, we measured the biochemical profile, platelet count,
hematocrit, platelet function, and coagulation before, during, and
after dialysis.
Methods
Subjects
Eleven patients (median age 37 years, range 22 to 51), with
chronic renal failure (creatinine clearance < 10 mI/mm) and on
maintenance hemodialysis were included. The patients gave in-
formed consent to participate. The study was approved by the
Ethics Committee of the Provincial Administration and the
University of the Orange Free State. The use of r-hirudin was
approved by the South African Medicines Control Council. All
patients refrained from taking drugs that may influence platelet
function and fibrinolysis for at least 10 days prior to, and during
the study.
Study design
This was an open cross-over study. Standard unfractionated
heparin from porcine intestinal mucosa (Heparin Sodium, Labe-
thica, SA) and r-hirudin (Hoechst AG, Frankfurt and Behring-
werke AG, Marburg, Germany) were used. Because of the
prolonged elimination of hirudin in terminal renal failure [18],
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Table 1. The mean decrease in serum levels of solutes during dialysis and the percent efficacy of dialysis with heparin and hirudin respectively
Hirudin
Decrease % Efficacy Decrease % Efficacy
Urea 13.2 1.9 mmol/liter 50 7 15.7 3.7 mmol/liter 51 7
Uric acid 0.2 0.1 mmol/liter 48 14 0.3 0.1 mmol/liter 50 11
Creatinine 423 152 jLmol/liter 45 6 439 149 jrmol/liter 44 6
r-hirudin was administered during the second dialysis of the study.
This was to avoid possible effects of residual r-hirudin during the
second dialysis. Cuprammonium rayon type artificial kidneys
(Terumo, Japan) were used once and then discarded. Dialysis was
done against an acetate buffer on a Gambro AK 10 artificial
kidney machine (Gambro, Sweden). Each dialysis session lasted
four hours.
The day before the first dialysis of the study (Day 0), blood (53
ml in 7 ml ACD-A) was collected, the platelets isolated and
labeled with 1111n-tropolone [19] and reinjected. One day later
(Day 1), dialysis with heparin was done. It was administered
according to the protocol in use at the Dialysis Unit. The total
intra-dialysis heparin dose during the four-hour dialysis session
varied between 5,000 and 10,000 IU. Two days later (Day 3), the
second dialysis was done with r-hirudin. A single bolus dose of
r-hirudin, 0.15 mg/kg dissolved in sterile pyrogen-free water, was
given at the start of blood flow through the extracorporeal circuit.
The heparin and r-hirudin were infused into the arterial side of
the extracorporeal circuit, between the pump and the artificial
kidney.
In a dose finding study dosages of 0.08 mg/kg (N = 2) and 0.12
mg/kg (N = 2) r-hirudin was found to be inefficient to prevent
occlusion.
Study variables
Platelet accumulation at the inlet of the artificial kidney. The
accumulation of '11lndium-labeled platelets was measured with a
Nal-scintillation probe. The probe was fixed in a position at the
inlet of the dialyzer. The radioactivity counts were expressed as
the increase over blood radioactivity (baseline). The latter was
measured after the first minute of blood flow through the dialyzer.
Laboratoiy analyses
Blood was collected at the arterial side of the extracorporeal
system. Serum levels of creatinine, urea and uric acid were
determined using a Technicon DAX analyzer (Bayer Diagnostics,
Basingstoke, UK). The platelet count and haematocrit were
determined with a Technicon H*1 blood cell analyzer (Bayer
Diagnostics) on blood collected in K3EDTA. Blood was collected
in 3.2% tn-sodium citrate (9:1 vol/vol) for the coagulation and ex
vivo platelet aggregation studies. The activated partial thrombo-
plastin time (APTT; Actin FS, Dade, Miami, FL, USA) and
thrombin time (TT; bovine thrombin; Dade) were measured with
a Cobas Fibro semi-automated optical system (Roche, Switzer-
land) [20]. The fibrinogen levels (derived fibrinogen) were mea-
sured with an Automated Coagulation Laboratory instrument
(Instrumentation Laboratory, Italy) according to the instructions
of the manufacturers [21]. The plasma antithrombin III (AT III)
levels were measured by means of a standard chromogenic assay
kit (Instrumentation Laboratory) with an Automated Coagulation
Laboratory instrument (Instrumentation Laboratory) [22]. Ex vivo
aggregation of platelets in response to ADP (0.5, 1.0, 1.5, 2.0, 10,
and 20 ILM) and epinephrine (10 j.LM) was measured as described
in detail [23]. Spontaneous platelet aggregation was also mea-
sured. The circulating platelet aggregate ratio (CPAR) was deter-
mined as described [24]. The plasma levels of heparin and
r-hirudin were determined in blood collected in 3.2% and 3.8%
tn-sodium citrate (9:1 vol/vol), respectively. The concentration of
heparin in the plasma and dialysate was determined with a
chromogenic assay kit (Instrumentation Laboratory) using the
Automated Coagulation Laboratory instrument. [25] The plasma
and dialysate concentrations of r-hirudin were determined with a
chromogenic substrate method [26].
Statistics
The effect of the specific anticoagulant on a variable within a
treatment regimen was determined by calculating the mean
difference (post-dialysis value — pre-dialysis value), and the 95%
confidence interval for the difference. The difference in effect
between treatments was determined by subtracting the change
during dialysis with r-hirudin from that measured during dialysis
with heparin. The 95% confidence interval for this difference was
calculated to compare the effect of the anticoagulants during
dialysis. The areas under the platelet accumulation
curves were calculated. The mean effects of the anticoagulant,
reflected by the relative sizes of the areas, were compared by
analysis of variance (ANOVA). The corresponding 95% confi-
dence interval was calculated for the difference between treat-
ments.
A double (hirudin) or single (heparin) exponential function was
fitted to the r-hirudin and heparin concentration in time profiles
of each individual to determine the plasma distribution and
elimination half-lives.
The results are given as a mean 1 SD if the results were
normally distributed. If not, the median and range are given.
Results
Biochemistiy
The mean decrease in urea, uric acid and creatinine after
dialysis, and the efficacy of dialysis with heparin and r-hirudin are
summarized in Table 1. Dialysis with r-hirudin was as effective as
dialysis with heparin since none of the values differed significantly
(P> 0.05).
Coagulation and plasma levels of heparin and r-hirudin
The changes in activated partial thromboplastin time (APTT)
and thrombin time (TI) during dialysis with heparin and r-
hirudin, respectively, are summarized in Table 2. Plasma levels of
fibninogen and AT III are given in Table 3. The difference
between the decrease in AT III levels during dialysis with heparin,
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Table 2. Activated partial thromboplastin time (APTT) and thrombin time ('IT) during dialysis with heparin and r-hirudin
Pre-dialysis 10 mm 60 mm 120 mm 180 mm 240 mm
APTI', seconds
Hirudin 30 to 38 65 to 103 53 to 82 51 to 75 48 to 76 46 to 70
Heparin 30 to 39 > 120 > 120 58 to > 120 36 to > 120 28 to > 120
TI, seconds
Hirudin 21 to 36 > 180 > 180 > 180 > 180 > 180
Heparin 24 to 38 > 180 > 180 > 180 55 to > 180 35 to > 180
Values are given as a range at each time interval.
Table 3. Changes in fibrinogen and antithrombin III levels during hemodialysis
Heparin Hirudin
Pre SI) 0 MD 1 S 95% CI Pre I SD a MD 1 SD 95% CI hHep — Hir 1 Sn 95% CI
Fibrmnogen,g/Iiler 4.0 1.5 0.4 0.7 —0.1;0.8 3.7 1.2 0.2 0.4 —0.1;0.5 —0.2 0.6 —0.5;0.2
AT III, % 83 20 —7 27 —25; 11 84 23 12 23 —3; 29 20 17 8; 31C
0 The effect of the anticoagulant on a variable within a treatment regimen was determined by calculating the mean difference (MD; post-dialysis value
minus pre-dialysis value) and the 95% confidence interval (CI).
The difference between treatments was determined by subtracting the change during dialysis with r-hirudin (Hir) from that measured during dialysis
with heparin (Hep). The 95% CI for this difference was also calculated to compare the anticoagulants during dialysis.
 0.05
Time, hours
Fig. 1. Changes in the plasma concentrations of heparin during the Ibur
hours of dialysis. Results are given as a mean 1 SuM.
and the increase during dialysis with r-hirudin, was significant (P
<0.05).
The changes in the plasma levels of heparin and r-hirudin are
summarized in Figures 1 and 2, respectively. The half-life of
heparin in the seven patients who did not receive maintenance
doses was 66 minutes (median; range from 42 to 225 mm). The
distribution half-life of r-hirudin was 11 minutes (median; range
from 5 to 24 mm) and the apparent elimination half-life was nine
hours (median; range from 2 to 107 hr). In eight of the patients
the elimination half-life ranged from 2 to 12 hours. In the
remaining three it was 20, 36 and 107 hours, respectively. No
r-hirudin or heparin was measured in the dialysate.
Accumulation of "In-labeled platelets
The accumulation of '11n-labeled platelets at the inlet of the
artificial kidney is given in Figure 3. The median for the areas
under the curves (AUC) for r-hirudin (0.66 hr X change from
baseline; range —0.22 to 3.88) was smaller than that for heparin
(1.22 hr >< change from baseline; range —0.36 to 8.09). The 95%
confidence interval (CI) for the difference between treatments
was from 1.0 to 2.49 hours X change from baseline.
Hematological measurements
Neither the platelet count nor the hematocrit changed signifi-
cantly within or between treatments.
Platelet function studies
The results are summarized in Table 4. There were no signifi-
cant differences within or between treatment regimens. However,
platelet aggregation in response to the higher concentrations of
ADP tended to be slightly inhibited after dialysis with heparin, but
not after dialysis with r-hirudin. The finding that there were no
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Fig. 2. Changes in the plasma concentrations of r-hirudin during the four
hours of dialysis. Results are given as a mean 1 SCM.
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The elimination half-life of heparin (90 mm) was similar to that
measured in normal humans [35, 36]. Heparin is partially depo-
lymerized by the cells of the monocyte-macrophage system and
the degradation products excreted by the kidneys [36, 371. The
potential for accumulation of degradation products may therefore
explain, at least in part, some of the complications of the
long-term use of heparin [4—8].
Markedly less 111In-labeled platelets accumulated at the inlet of
the artificial kidney during dialysis with r-hirudin. Excessive
platelet deposition, especially during the first three hours of
dialysis, was prevented by r-hirudin (Fig. 3). This may have
resulted in a smaller loss of hollow fiber volume because there is
a strong relationship between the number of platelets deposited
and loss of volume [381. In this case dialysis with r-hirudin could
have been more effective during this time. Unfortunately we did
not measure it. The fact that deposition of platelets after three
hours of dialysis were similar for both anticoagulants suggests that
a minimum number of platelets will always accumulate in the
artificial kidney. This assumption is supported by the findings that
D-Phe-Pro-Arg CH2CI, a synthetic and direct thrombin inhibitor,
completely prevents platelet deposition onto native Dacron vas-
cular graft material [38], but was not able to do the same in
artificial kidneys [39].
There are several possible reasons why heparin is not as
effective as hirudin in inhibiting arterial thrombus formation.
These include: (a) heparin may contain fractions that activate
platelets directly, thereby promoting thrombogenesis [40]; (b)
activated platelets release proteins, such as platelet factor 4 and
beta-thromboglobulin, that can inactivate heparin locally at the
surface of thrombi [41]; (c) the inactivation of thrombin bound to
other components in a thrombus may be prevented by steric or
ionic hindrance of the heparin-AT III complex [42]; and (d)
platelets within a thrombus may be activated by meizothrombin
which is not inactivated by the heparin-AT III complex [43].
The AT III levels decreased during dialysis with heparin and
increased during dialysis with r-hirudin. The decrease after hep-
arm dialysis is not surprising and can be attributed to consumption
of AT III by heparin to inactivate thrombin [44]. However, the
decrease was not substantial and is possibly of little clinical
significance. Moreover, the decrease was transient since the AT
III levels before dialysis with r-hirudin were similar to that before
dialysis with heparin. The increase in AT III levels after dialysis
with r-hirudin is difficult to explain. It cannot result from
hemoconcentration [45] since the hematocrit did not change
markedly. AT III is an acute phase protein. The slight increase
during dialysis with r-hirudin may indicate that there was a slight
consumption of AT III. That can be explained by the pre-phase
enzyme activation of Factor IX, Factor X, and others. When
r-hirudin is used, these factors are activated and bound by AT III.
To our knowledge only one study investigated the use of
r-hirudin during hemodialysis in humans [17]. In that study a dose
of 0.08 mg/kg was effective to prevent occlusion of the extracor-
poreal circuit. In our dose finding study this dose and even a
higher dose of 0.12 mg/kg was too low to prevent thrombus
formation in the extracorporeal circuit. We therefore used a dose
of 0.15 mg/kg.
In conclusion, this study demonstrates the feasibility of using
r-hirudin in patients undergoing hemodialysis. The results indi-
cate that an intravenous bolus of 0.15 mg/kg r-hirudin was safe
and effective. Since it is administered as a single pre-dialysis dose,
Fig. 3. The relative accumulation of "Indium-labeled platelets, expressed
as the fold increase from baseline at the inlet of the artificial kidney during
dialysis with heparin (——) and r-hirudin (- - U - -), respectively. Results are
given as a mean 1 SEM.
increases in circulating platelet aggregates is surprising, but might
have been influenced by the site of sample collection.
This study in patients clearly demonstrates that r-hirudin can be
used successfully as anticoagulant during hemodialysis. The per-
cent decrease in plasma creatinine, urea and uric acid were
equivalent for both anticoagulants, indicating that dialysis with
r-hirudin was as effective as dialysis with heparin. When compared
to heparin, effective dialysis with r-hirudin was achieved at a
shorter APTT (Table 2). This is of particular importance since a
prolonged APTF is associated with an increased risk of bleeding
[26, 27]. The changes observed in the IT is probably of no clinical
relevance because the iT is an extremely sensitive test of throm-
bin inhibition. Therefore it is not indicative of the anticoagulation
status or of a bleeding risk [28, 29].
The longer elimination half-life of r-hirudin is a matter of
concern. However, one must take into account that it is perhaps
not ideal to derive the long half-lives from the course of plasma
levels determined from samples collected only for four hours. Our
results does compare favorably with that measured in patients
with chronic renal failure and chronic renal disease [18], and is
considerably longer than that measured in normal humans and
animals [30—34]. The prolonged half-life provides a long-lasting
anticoagulant effect and the potential for drug accumulation. This
needs to be investigated. The reason for the large variation in
elimination times of r-hirudin from the plasma of individual
patients is not clear. There was no correlation between the
elimination times and the baseline creatinine, urea or uric acid
values. The large variation may require that the dosages be
individually adjusted when repeated treatments are given. A
possible solution may be to treat the dialyzer and not the patient,
in which case a dialyzer with a larger cut-off value will have to be
used, together with a constant infusion of r-hirudin at the inlet of
the dialyzer. In this study the dialyzers had a cut-off value of 5 kD
which prevented the removal of r-hirudin by the dialysis process.
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Table 4. Changes in the circulating platelet aggregate ratio (CPAR) and platelet aggregation during hemodialysis
Heparin 1-lirudin
hHep — Hir I SD 95% CIPre I SD "MD 1 SD 95% Cl Pre I SD MD 95% CI
CPAR 0.81 0.14 0.00 0.11
—0.07; 0.07 0.78 0.12 0.05 0.13 —0.04; 0.13 0.04 0.19 —0.08 ; 0.17
Aggregation, %
Spontaneous 4.6 1.6 1.0 1.7 —0.03 ; 2.2 4.5 2.0 0.6 2.7 —1.3; 2.5 —0.4 3.5 —2.9; 2.2
Adrenalin 10 xM 55.9 9.6 —3.2 10.5 —1.07 ; 4.3 58.9 8.4 —7.3 16.0
—18.7; 4.1 —4.1 18.5 —17.3 ; 9.1
ADP : 0.5 jrM 9.0 5.6 22 3.9 —0.8 ; 5.2 15.9 14.8 —4.5 6.9
—8.6; 3.6 —3.8 6.3 —9.1 ; 1.5
1.0 sM 26.9 16.2 —4.5 17.2 —16.8; 7.8 25.1 15.7 —4.0 10.1 —11.2; 3.2 0.5 23.9 —16.6; 17.6
1.5 sM 46.5 16.4 10.0 19.0 —23.7; 3.5 44.6 13.5 0.0 19.5 —13.9; 13.9 10.1 16.6 —2.0; 22.1
2.0 jM 52.6 16.2 —6.9 13.4 —16.5 ; 2.7 52.0 10.8 —1.0 16.9 —13.1 ; 11.1 5.9 20.7 —8.9; 20.7
10.0 jsM 61.6 9.8 —5.8 9.1 —12.2;0.8 61.6 10.7 1.8 12.1 —6.9; 10.5 7.6 15.4 —4.5; 17.6
20.0 jsM 63.0 9.3 —3.6 8.5 —9.7; 2.5 654 12.4 2.9 12.1 —57; 11.6 6.6 15.4 —4.5; 17.6
The effect of the anticoagulant on a variable within a treatment regimen was determined by calculating the mean difference (MD; post-dialysis value
minus pre-dialysis value) and the 95% confidence interval (CI).
b Thedifference between treatments was determined by subtracting the change during dialysis with r-hirudin (Hir) from that measured during dialysis
with heparin (Hep). The 95% CI for this difference was also calculated to compare the anticoagulants during dialysis.
it will simplify the dialysis procedure. The shorter APTT indicates
a reduced risk of developing a bleeding tendency. The fact that
less platelets accumulated at the inlet of the dialyzer indicates that
the dose was sufficient to protect against thrombus formation. In
addition no side effects, bleeding complications or thrombotic
events occurred with the use of r-hirudin. These findings, together
with the fact that r-hirudin can be used successfully in patients
with an AT III deficiency and in patients with heparin-induced
thrombocytopenia [35], indicate that r-hirudin may be a suitable
and better alternative for heparin as anticoagulant. In this study
r-hirudin was used in only one dialysis session in each of a
relatively small number of patients. Therefore, final conclusions
and recommendations cannot be made. It will be worthwhile to
investigate the use of r-hirudin in a larger number of patients who
are undergoing serial dialysis two to three times per week.
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